Institut Bordet - Retour à la page d'accueil
en
I want to donate to research

Nathalie Meuleman

Department : Hematology
Speciality : Head of Department
 
nathalie.meuleman [at] bordet.be

Publications

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.

Authors : Bobin A, Kyheng M, Guidez S, Gruchet-Merouze C, Richez V, Duhamel A, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Perrot A, Roussel M, Jaccard A, Petillon MO, Belhadj-Merzoug K, Chretien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Moreau P, Avet-Loiseau H, Hulin C, Facon T, Leleu X
Year : 2022
Journal : Leukemia

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis.

Authors : Massaro F, Meuleman N, Bron D, Vercruyssen M, Maerevoet M
Year : 2022
Journal : Cancers (Basel)

Immuno-comparative screening of adult-derived human liver stem/progenitor cells for immune-inflammatory-associated molecules.

Authors : Merimi M, Lagneaux L, Lombard CA, Agha DM, Bron D, Lewalle P, Meuleman N, Najimi M, Sokal EM, Najar M
Year : 2021
Journal : Inflamm Res

Biomarkers for Early Diagnosis of Hemophagocytic Lymphohistiocytosis in Critically Ill Patients.

Authors : Debaugnies F, Mahadeb B, Nagant C, Meuleman N, De Bels D, Wolff F, Gottignies P, Salaroli A, Borde P, Voué M, Corazza F
Year : 2021
Journal : J Clin Immunol

Case reports of medication-related osteonecrosis of the jaw (MRONJ) treated with uncultured stromal vascular fraction and L-PRF.

Authors : Bouland C, Meuleman N, Widelec J, Keiani-Mothlagh K, Voisin C, Lagneaux L, Philippart P
Year : 2021
Journal : J Stomatol Oral Maxillofac Surg

More publications »

Follow us!

Youtube

The New Jules Bordet Institute.

The New Jules Bordet Institute, located on the university campus of the ULB in Anderlecht, is ready and will soon welcome its first patients. A new state-of-the-art hospital entirely dedicated to the fight against cancer.